Ahead of the ICRS Summit in Porto, SmartTRAK interviews Past President Dr. Daniel Grande on key joint restoration breakthroughs, including landmark cartilage therapies, extracellular vesicles and mitochondrial transplantation.
In this interview with SmartTRAK, Daniel Grande, PhD, past president of the International Cartilage Regeneration & Joint Preservation Society (ICRS), delves into key scientific topics to be covered at the upcoming ICRS Summit in Porto, Portugal. Dr. Grande explores key breakthroughs transforming joint restoration, including landmark cartilage therapies, extracellular vesicles, mitochondrial transplantation, and advances in joint preservation.
To listen to the interview, click on the following video (30:00 min). A link to download a complete transcript of the interview is also provided below.
Interview Transcript
SmartTRAK: The title of the summit is Regenerative Era is Underway. Given your experience in the space, seeing technologies come and go, what aspects make you feel that the regenerative era is underway, rather than it being more hype than actual? What makes you think it's more real now?
Dr. Daniel Grande: Well, I would say that first of all, with the recent things, recent events such as the FDA approval of AGILI-C, which is, I think, a landmark, because that's one of the first not only cartilage repair products that are available, but also for osteoarthritis. So, it has a dual mode of action. I see Kolon TissueGene in phase three clinical trials. That's exciting, because their approach is a little different in that it's more of what I view as one of the challenges in osteoarthritis, which is that there's more than... It's not just treating the disease of cartilage per se, but the organ system that is the joint. And this concept of return to homeostasis is a hallmark of my intrinsic belief in what we need to do to convert just one product into something that's treating the whole joint as a whole. So M1 macrophages to M2s are kind of my new dream, combined with an anabolic procedure such as AGILI-C or another program like that.
And then, of course, having been involved with the earliest cell-based therapies for cartilage, the advent of the MACI is something that I'm very glad to see the continued evolution of that. But more importantly, I think, and I still am not sure why this is the case, but why there isn't more allogenic off-the-shelf availability of that, and why is that ...
Interested in key joint restoration breakthroughs, including landmark cartilage therapies, extracellular vesicles, and mitochondrial transplantation? To learn more, click the button below to download a complete transcript of SmartTRAK GM/Sr Analyst David Shepherd's exclusive interview with Daniel Grande, PhD, past president of ICRS and Director of the Orthopedic Research Institute at the Feinstein Institute for Medical Research.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
